Journal of Clinical Oncology
Articles in this Issue
From diagnosis to survivorship: Mapping the lived experience of patients with cancer in the Philippines.
e13619 Background: Cancer is now the Philippines’ second leading cause of death, yet the day-to-day realities of care rema...
Analysis of recurrence and risk factors in resectable early-stage adenocarcinoma with uncommon <i>EGFR</i> mutations: A comprehensive cohort study in South Korea.
8038 Background: This study aimed to identify clinicopathologic factors associated with recurrence in patients with surgic...
Clinical outcomes and treatment sequencing effects in well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors.
e16311 Background: Following the 2017 WHO reclassification, well-differentiated grade 3 neuroendocrine tumors (WDG3 NETs)...
Stratifying survival benefit of encorafenib/cetuximab (EC) in BRAF V600E–mutant mCRC using clinical and inflammatory biomarkers: Real-world experience from greater Manchester.
e15563 Background: BRAF V600E-mutant metastatic colorectal cancer (mCRC) is an aggressive subtype with historically poor o...
Temporal trends and sociodemographic differences in influenza vaccination among U.S. cancer survivors, 2005-2024.
1674 Background: Given the increased risk of complications and adverse outcomes associated with influenza infection among...
Safety of immune checkpoint inhibitors in solid tumor patients with hepatitis C: A real-world analysis.
11158 Background: Patients with hepatitis C virus (HCV) infection are commonly excluded from immune checkpoint inhibitor (...
Artificial intelligence–assisted treatment decision-making for cancer multidisciplinary team meetings: A proof of concept study.
e13673 Background: Multi-Disciplinary Team Meetings (MDTMs) are “gold standard” in the UK Cancer Care continuum. Multiple,...
Differential immune gene signatures to inform clinical course of patients with metastatic colorectal cancer.
e15592 Background: Patients with proficient mismatch repair (pMMR) colorectal cancer liver metastases (CRLM) constitute a...
A phase 1 dose-escalation and -expansion study of AFN0328, a novel mRNA-based immunotherapy, in patients with HPV16/18-associated high-grade squamous intraepithelial lesions.
5544 Background: Persistent infection with high-risk human papillomavirus (HPV), particularly HPV16 and HPV18, drives the...
Targeting metal ion transport in pancreatic cancer: A prognostic signature and GraphBAN-predicted therapeutics framework.
e16000 Background: Pancreatic ductal adenocarcinoma (PDAC) remains a lethal malignancy with limited therapeutic op...
Closing the gap in HER2 testing: CEP17-low FISH results and NGS discordance.
e15192 Background: Discordance between HER2 amplification detected by fluorescence in situ hybridization (FISH) and next-g...
Response-focused analyses of the impact of circadian rhythm on efficacy of first-line immunotherapy in melanoma.
9520 Background: Several retrospective studies have associated better clinical outcomes with morning infusions of immune-c...
Metastatic breast cancer-related mortality with thoracic involvement among U.S. adults aged ≥ 25 years: A retrospective CDC WONDER analysis from 1999 to 2024.
e13094 Background: Breast cancer is one of the most commonly diagnosed malignancies and a leading cause of cancer-related...
Promise or predicament? Real-world analysis of molecular targets and therapy approaches in uro-oncology.
e17022 Background: Despite ongoing research and evolving therapeutic landscapes, advanced urological malignancies such as...
Real-world outcomes of cabazitaxel plus carboplatin versus cabazitaxel alone in metastatic castration-resistant prostate cancer.
e17044 Background: Cabazitaxel is an established treatment for metastatic castration-resistant prostate cancer (mCRPC). In...
The HOUSES index: A novel, patient-level measure of socioeconomic status linking real-world housing data to overall survival in metastatic pancreatic ductal adenocarcinoma.
e13719 Background: Previous research has demonstrated disparities in survival outcomes for patients with pancreatic ductal...
Lambert-Eaton myasthenic syndrome in United States veterans with small cell lung carcinoma (SCLC).
e20148 Background: Lambert-Eaton Myasthenic Syndrome (LEMS) is a rare autoimmune disorder characterized by muscle weakness...
Indirect comparison of the effectiveness of tepotinib and immunotherapy in NSCLC with METex14 skipping alterations: Final propensity-scored analysis of eight pooled real-world datasets (TOGETHER) vs the VISION trial.
e20751 Background: Tepotinib demonstrated clinical efficacy in NSCLC patients with MET...
Cladribine/cyclophosphamide lymphodepletion efficacy and toxicity in CD19 CAR-T therapy for B-ALL.
6549 Background: During an international fludarabine (Flu) shortage, our center adopted cladribine (Cla) as a substitute f...
Cancer-associated left ventricular thrombus in hospitalized oncology patients: National burden and inpatient outcomes.
e23230 Background: Left ventricular thrombus is an uncommon, but high-risk cardiac finding that may reflect acute cardio-o...
Healthcare system gaps in access to HER2-directed chemotherapy in early-stage HER2-positive breast cancer: A scoping review.
e13031 Background: HER2-directed targeted treatment with Trastuzumab and chemotherapy has been the standard therapy for ea...
Development of a shared neoantigen peptide library to promote personalized vaccine strategy in patients with non–small cell lung cancer.
e20624 Background: To establish and validate a shared neoantigen peptide library based on NSCLC hotspot mutations for effi...
Low-dose nivolumab in patients at high risk of immune-related adverse events: A retrospective cohort study.
2656 Background: Immune checkpoint inhibitors (ICIs) are relatively contraindicated in patients with prior severe immune-r...
Racial and ethnic disparities in survival among patients with early-onset primary liver cancer: A 15-year SEER analysis.
e13749 Background: Early-onset liver cancer is increasingly recognized as a distinct clinical entity, yet population-level...
Performance status and tarlatamab outcomes in a large, multi-institution real-world database of 2L+ ES-SCLC.
e20120 Background: Tarlatamab is a novel bispecific T-cell engager approved for 2L+ extensive stage small cell lung cancer...